Dr Michael Baker presents at the Euroz Hartleys 2025 Healthcare Forum
MELBOURNE, AUSTRALIA 04 February 2025: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that its CEO and MD, Dr Michael Baker, will today present at the Euroz Hartleys 2025 Healthcare Forum.
Dr Baker will present key pre-clinical data and clinical plans for Arovella’s CAR-iNKT cell therapy platform and describe how Arovella’s technology provides important advantages over existing T-cell therapies and has the potential to be applied to both blood cancers and solid tumours. T
